Cargando…
Can Three Months of Teriparatide Be One of Treatment Options for Osteoporotic Vertebral Compression Fracture Patients?
OBJECTIVE: Osteoporosis is one of the most common causes of vertebral compression fractures (VCFs). Teriparatide, a recombinant human parathyroid hormone, is the first anabolic agent for the treatment of osteoporosis. The aim of this study was to determine whether 3 months of teriparatide could be e...
Autores principales: | Kang, Jung Hoon, Yang, Sang Mi, Im, Soo Bin, Jeong, Je Hoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Neurotraumatology Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6495587/ https://www.ncbi.nlm.nih.gov/pubmed/31098345 http://dx.doi.org/10.13004/kjnt.2019.15.e13 |
Ejemplares similares
-
At Least One Cyclic Teriparatide Administration Can Be Helpful to Delay Initial Onset of a New Osteoporotic Vertebral Compression Fracture
por: Suk, Kyung Soo, et al.
Publicado: (2014) -
The Application of Vertebral Augmentation Procedures and Teriparatide in the Treatment of Osteoporotic Vertebral Compression Fractures [Response to Letter]
por: Kong, Meng, et al.
Publicado: (2020) -
Analysis of radiologic and clinical outcome in acute osteoporotic vertebral compression fracture: Single-agent teriparatide vs. teriparatide with subsequent vertebroplasty()
por: Jin, Yongjun
Publicado: (2023) -
Effects of teriparatide on lung function and pain relief in women with multiple osteoporotic vertebral compression fractures
por: Chen, Chien-Min, et al.
Publicado: (2014) -
Could Teriparatide Replace Percutaneous Vertebral Augmentation for Patients with Osteoporotic Vertebral Compression Fracture to Some Extent? [Letter]
por: Zhou, Jiaming, et al.
Publicado: (2019)